Crohn's Disease [clinicaltrials_resource:bbc8f1da7f5aefd3d2f50780528bc332]
Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease [clinicaltrials:NCT00004423]Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease [clinicaltrials:NCT00004941]Monoclonal Antibody Treatment of Crohn's Disease [clinicaltrials:NCT00007163]G-CSF to Treat Crohn's Disease [clinicaltrials:NCT00025805]Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease [clinicaltrials:NCT00032786]Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease [clinicaltrials:NCT00032799]Multicenter Trial For Patients With Acute Crohn's Disease [clinicaltrials:NCT00035503]CP-461 for the Treatment of Crohn's Disease [clinicaltrials:NCT00042055]Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease [clinicaltrials:NCT00048113]Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease [clinicaltrials:NCT00048295]Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease [clinicaltrials:NCT00055367]clinicaltrials:NCT00055497A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease [clinicaltrials:NCT00055523]Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease [clinicaltrials:NCT00055536]Quality of Life in Pediatric Inflammatory Bowel Disease [clinicaltrials:NCT00061737]Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease [clinicaltrials:NCT00072839]A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease [clinicaltrials:NCT00072943]An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease [clinicaltrials:NCT00074542]Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease [clinicaltrials:NCT00077779]A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease [clinicaltrials:NCT00078611]STA-5326 in Crohn's Disease Patients [clinicaltrials:NCT00088062]clinicaltrials:NCT00098111Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease [clinicaltrials:NCT00101946]Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease [clinicaltrials:NCT00105300]An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease [clinicaltrials:NCT00106314]clinicaltrials:NCT00109473Imuran Dosing in Crohn's Disease Study [clinicaltrials:NCT00113503]VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease [clinicaltrials:NCT00114465]Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease [clinicaltrials:NCT00114803]clinicaltrials:NCT00130390clinicaltrials:NCT00132899Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease [clinicaltrials:NCT00138840]Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients [clinicaltrials:NCT00138879]Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). [clinicaltrials:NCT00152425]A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo) [clinicaltrials:NCT00152490]Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis [clinicaltrials:NCT00152841]clinicaltrials:NCT00160524clinicaltrials:NCT00160706clinicaltrials:NCT00162942The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels [clinicaltrials:NCT00167882]
condition [clinicaltrials_vocabulary:condition]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Crohn's Disease [clinicaltrials_resource:bbc8f1da7f5aefd3d2f50780528bc332]
Bio2RDF identifier
bbc8f1da7f5aefd3d2f50780528bc332
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bbc8f1da7f5aefd3d2f50780528bc332
identifier
clinicaltrials_resource:bbc8f1da7f5aefd3d2f50780528bc332
title
Crohn's Disease
@en
label
Crohn's Disease [clinicaltrials_resource:bbc8f1da7f5aefd3d2f50780528bc332]
@en